Format

Send to

Choose Destination
Br J Surg. 2016 Jun;103(7):855-62. doi: 10.1002/bjs.10121. Epub 2016 Apr 4.

Multicentre study of neoadjuvant chemotherapy for stage I and II oesophageal cancer.

Author information

1
Department of Digestive and Oncological Surgery, Claude Huriez University Hospital, Lille, France.
2
North of France University, Lille, France.
3
Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche S1172, Team 5 'Mucins, epithelial differentiation and carcinogenesis', Jean-Pierre Aubert Research Centre, Lille, France.
4
Department of Pathology, Lille University Hospital, Lille, France.
5
Department of Biostatistics, Lille University Hospital, Lille, France.
6
Site de Recherche Intégré en Cancérologie OncoLille, Lille, France.
7
Department of Digestive Surgery, Edouard Herriot University Hospital, Lyon, France.
8
Cavale Blanche University Hospital, Brest, France.
9
Estaing University Hospital, Clermont-Ferrand, France.
10
Pontchaillou University Hospital, Rennes, France.
11
Haut-Levêque University Hospital, Bordeaux, France.

Abstract

BACKGROUND:

The benefit of neoadjuvant chemotherapy (NCT) for early-stage oesophageal cancer is unknown. The aim of this study was to assess whether NCT improves the outcome of patients with stage I or II disease.

METHODS:

Data were collected from 30 European centres from 2000 to 2010. Patients who received NCT for stage I or II oesophageal cancer were compared with patients who underwent primary surgery with regard to postoperative morbidity, mortality, and overall and disease-free survival. Propensity score matching was used to adjust for differences in baseline characteristics.

RESULTS:

Of 1173 patients recruited (181 NCT, 992 primary surgery), 651 (55·5 per cent) had clinical stage I disease and 522 (44·5 per cent) had stage II disease. Comparisons of the NCT and primary surgery groups in the matched population (181 patients in each group) revealed in-hospital mortality rates of 4·4 and 5·5 per cent respectively (P = 0·660), R0 resection rates of 91·7 and 86·7 per cent (P = 0·338), 5-year overall survival rates of 47·7 and 38·6 per cent (hazard ratio (HR) 0·68, 95 per cent c.i. 0·49 to 0·93; P = 0·016), and 5-year disease-free survival rates of 44·9 and 36·1 per cent (HR 0·68, 0·50 to 0·93; P = 0·017).

CONCLUSION:

NCT was associated with better overall and disease-free survival in patients with stage I or II oesophageal cancer, without increasing postoperative morbidity.

PMID:
27040445
DOI:
10.1002/bjs.10121
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center